Literature DB >> 9266097

Changes of biological features in breast cancer cells determined by primary chemotherapy.

A Frassoldati1, F Adami, C Banzi, M Criscuolo, L Piccinini, V Silingardi.   

Abstract

BACKGROUND: To evaluate the changes in the biological features of breast cancer cells induced by primary chemotherapy (PCT) and their possible relationship with the response to therapy we performed an extensive immunohistochemical study before and after PCT. PATIENTS AND METHODS: PCT was administered to 29 women with breast cancer. On specimens obtained by tru-cut and post-chemotherapy surgery we analyzed the following parameters: histology, histologic grade, apoptotic index, hormone receptor levels, Ki67, PCNA, EGFr, bcl-2, p53, p170. The significance of the changes induced by PCT and their correlations with the type of response were evaluated.
RESULTS: Twelve patients achieved a partial response with PCT. No baseline biological parameter correlated with the type of response. After PCT we observed a significant increase in the apoptotic index (p = 0.000), PCNA (p = 0.036), EGFr (p = 0.005), and p170 expression (p = 0.001), regardless of the type of chemotherapy administered (anthracyclines, 25 cases, or CMF, 4 cases). Responder patients displayed a significant decrease in ER levels (p = 0.015), whereas in non responders there was an increase in PCNA (p = 0.008) and EGFr expression (p = 0.002). The apoptotic index and p170 expression rose after PCT regardless of the type of response.
CONCLUSIONS: PCT induced significant variations in the phenotype of breast cancer cells. These changes might reflect the selection of new neoplastic clones with different biological properties and so could facilitate the choice of appropriate chemotherapy agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266097     DOI: 10.1023/a:1005875002458

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.

Authors:  Norbert Arens; Uwe Bleyl; Ralf Hildenbrand
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

2.  BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy.

Authors:  H Strik; M Deininger; J Streffer; E Grote; J Wickboldt; J Dichgans; M Weller; R Meyermann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

3.  The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer.

Authors:  Veronique F Cocquyt; Vera R Schelfhout; Phillip N Blondeel; Herman T Depypere; Kristof K Daems; Rudolphe F Serreyn; Marleen M Praet; Simon J P Van Belle
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

4.  Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.

Authors:  Ksenija Kanjer; Svetislav Tatić; Zora Nešković-Konstantinović; Zaki Abu Rabi; Dragica Nikolić-Vukosavljević
Journal:  Pathol Oncol Res       Date:  2013-03-24       Impact factor: 3.201

Review 5.  A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.

Authors:  Ikuo Sekine; Chikako Shimizu; Kazuto Nishio; Nagahiro Saijo; Tomohide Tamura
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

6.  Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients.

Authors:  L Moureau-Zabotto; S Ricci; J P Lefranc; F Coulet; C Genestie; M Antoine; S Uzan; J P Lotz; E Touboul; R Lacave
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

7.  Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer.

Authors:  A Bottini; A Berruti; A Bersiga; M P Brizzi; P Bruzzi; S Aguggini; A Brunelli; G Bolsi; G Allevi; D Generali; E Betri; G Bertoli; P Alquati; L Dogliotti
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

8.  Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.

Authors:  M G Daidone; A Luisi; G Martelli; E Benini; S Veneroni; G Tomasic; G De Palo; R Silvestrini
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy.

Authors:  Shi-Xin Yang; Wings T Y Loo; Louis W C Chow; Xin-hua Yang; Yi Zhan; Lin-Jun Fan; Fan Zhang; Li Chen; Qing-liang Wang; Hua-Liang Xiao; Jin-Long Wu; Xiu-wu Bian; Jun Jiang
Journal:  J Transl Med       Date:  2012-09-19       Impact factor: 5.531

10.  Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.

Authors:  Vinay Singhal; J P Singh; Ashima Lyall; Sunita Saxena; Anju Bansal
Journal:  BMC Cancer       Date:  2004-08-13       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.